Soleno Therapeutics (NASDAQ:SLNO) and Yubo International Biotech (OTCMKTS:YBGJ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.
Risk and Volatility
Soleno Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Yubo International Biotech has a beta of 7.19, suggesting that its share price is 619% more volatile than the S&P 500.
37.1% of Soleno Therapeutics shares are held by institutional investors. 17.7% of Soleno Therapeutics shares are held by insiders. Comparatively, 56.5% of Yubo International Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and target prices for Soleno Therapeutics and Yubo International Biotech, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Yubo International Biotech||0||0||0||0||N/A|
Soleno Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 793.85%. Given Soleno Therapeutics’ higher possible upside, analysts plainly believe Soleno Therapeutics is more favorable than Yubo International Biotech.
Valuation & Earnings
This table compares Soleno Therapeutics and Yubo International Biotech’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Soleno Therapeutics||N/A||N/A||-$24.64 million||($0.39)||-2.29|
|Yubo International Biotech||N/A||N/A||N/A||N/A||N/A|
This table compares Soleno Therapeutics and Yubo International Biotech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Yubo International Biotech||N/A||-177.14%||-19.87%|
Soleno Therapeutics Company Profile
Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The firm focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Yubo International Biotech Company Profile
Yubo International Biotech Ltd. engages in the supply of products that process, store and administer therapeutic doses of endometrial stem cells for treatment of disease and injuries. Its products include Life Shinkansen Liquid Dressing and Life Shinkansen Spray Dressing. The company was founded by Lawrence A. Minkoff on February 22, 1991 and is headquartered in Beijing, China.
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.